Personalized Radiation Therapy for GBM

Completed · Not applicable

Conditions studied: Glioblastoma

In brief

The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.

Key facts

Study ID

NCT03477513

Run by

Abramson Cancer Center at Penn Medicine

People needed

23

Starts

2018-03-01

Expected to finish

2026-05-21

Last updated by the study team

2026-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
• Age 18 or older
• Ability to give signed informed consent
• Karnofsky Performance Status (KPS) at least 70

You may not qualify if…

• Placement of Gliadel wafers
• Participation in another investigational trial
• Active treatment of another malignancy

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.